Stephen Richardson, Managing Consultant, Author at EverGlade Consulting

mRNA infectious diseases vaccine development

BARDA Issues RPP for Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability

Leave a Comment / BARDA, EverGlade Insights / By Stephen Richardson, Managing Consultant

24-08-mRNALongTerm_Final The Biomedical Advanced Research and Development Authority (BARDA) has released a Request for Project Proposals (RPP) aimed at vaccine development and response for emerging infectious diseases and rapid pandemic influenza. The RPP, numbered RRPV-24-08-mRNALongTerm, focuses on creating a lasting partnership that builds and maintains a robust mRNA preparedness and response system for pandemic influenza […]

BARDA Issues RPP for Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability Read More »

DTRA Issues SOO for Broad-Spectrum Therapeutics

Leave a Comment / DTRA, EverGlade Insights / By Stephen Richardson, Managing Consultant

August-24-Broad-Spectrum-SOO The Defense Threat Reduction Agency (DTRA) has released a Statement of Objectives (SOO) to develop prototype Medical Countermeasures (MCMs) aimed at addressing therapeutic indications of Warfigher exposure to viral and bacterial biothreat agents. Key Information and Deadlines The Project Agreement Holder must state if their proposal is for the solution of the objecties of

DTRA Issues SOO for Broad-Spectrum Therapeutics Read More »

ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT)

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By Stephen Richardson, Managing Consultant

DECIDE_ET_Solicitation_DRAFT The Advanced Research Projects Agency for Health (ARPA-H) has introduced the Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic (ET), representing a crucial initiative designed to revolutionize the production and validation of autologous cell therapies. This ET targets significant enhancements in the production processes at Academic Medical Centers (AMCs), focusing on

ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT) Read More »

ARPA-H Announces RFP for Cancer Intervention and Detection

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By Stephen Richardson, Managing Consultant

24-SOL-109+POSEIDON+DRAFT+ISO_9+AUG+24 The Advanced Research Projects Agency for Health (ARPA-H) has issued a Request for Proposals (RFP) for the POSEIDON program, a groundbreaking initiative aimed at advancing cancer screening technologies. The Platform Optimizing SynBio for Early Intervention and Detection in Oncology (POSEIDON) seeks to develop innovative, non-invasive tests that can detect multiple cancers at an early

ARPA-H Announces RFP for Cancer Intervention and Detection Read More »

JPM & JPEO Issues RFI for Host-Directed Therapeutics for Prophylaxis

Leave a Comment / EverGlade Insights, JPEO / By Stephen Richardson, Managing Consultant

Evaluation Criteria White Paper Template W911SR-24-S-HDTX+RFI The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), along with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), invites stakeholders from industry, academia, and nonprofit sectors to submit white papers for the development and repurposing of host-directed therapeutics.

JPM & JPEO Issues RFI for Host-Directed Therapeutics for Prophylaxis Read More »

Senior chemist analysing blood sample while working overtime in chemistry equipped laboratory.

ARPA-H Announces Proposers’ Day for New POSEIDON Program

Leave a Comment / ARPA-H, EverGlade Insights / By Stephen Richardson, Managing Consultant

Proposers’ Day Notice 24-SOL-109+POSEIDON+DRAFT+ISO_9+AUG+24 The Advanced Research Projects Agency for Health (ARPA-H) has recently unveiled an exciting initiative named POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in ONcology). This program aims to drastically shift the current landscape of cancer detection through innovative, synthetic biology-based approaches. As part of this groundbreaking venture, ARPA-H is

ARPA-H Announces Proposers’ Day for New POSEIDON Program Read More »

BARDA Issues RPP for N95 Respirator Production

Leave a Comment / BARDA, EverGlade Insights / By Stephen Richardson, Managing Consultant

BioMaP_RPP_24-05-N95 The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at sustaining the manufacturing capacity of N95 respirators, a crucial element in the biopharmaceutical and healthcare sectors, especially highlighted during the COVID-19 pandemic. The RPP, numbered 24-05-N95, focuses on maintaining a “warm-base” status of manufacturing capabilities

BARDA Issues RPP for N95 Respirator Production Read More »

BARDA Issues RFI for Developing Single-Dose Pandemic Influenza Vaccine

Leave a Comment / BARDA, EverGlade Insights / By Stephen Richardson, Managing Consultant

The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration
for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human
Services (HHS), is seeking innovative ideas and strategies to develop a single-dose vaccine for pandemic
influenza. This Request for Information (RFI) is designed to gather valuable insights from
biopharmaceutical companies, research institutions, and vaccine development experts to facilitate the
creation of a vaccine that offers durable immunity with a single administration.

BARDA Issues RFI for Developing Single-Dose Pandemic Influenza Vaccine Read More »

BARDA Announces Request for Project Proposal for On-Demand Manufacturing

Leave a Comment / BARDA, EverGlade Insights / By Stephen Richardson, Managing Consultant

The Biomedical Advanced Research and Development Authority (BARDA) is spearheading this effort with its innovative On-Demand Manufacturing program. This initiative is designed to revolutionize the production and distribution of MCMs by developing portable, continuous, and end-to-end manufacturing systems.

BARDA Announces Request for Project Proposal for On-Demand Manufacturing Read More »

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D

Leave a Comment / BARDA, EverGlade Insights / By Stephen Richardson, Managing Consultant

BARDA has recently unveiled significant updates to its BAA, emphasizing a more refined and responsive approach to public health preparedness. Amendment 4 introduces crucial changes to the Areas of Interest designed to align BARDA’s efforts with the evolving landscape of global health threats.

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D Read More »

BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D

Leave a Comment / BARDA, EverGlade Insights / By Stephen Richardson, Managing Consultant

The Biomedical Advanced Research and Development Authority (BARDA) has recently unveiled significant updates to its Broad Agency Announcement (BAA), emphasizing a more refined and responsive approach to public health preparedness. Amendment 3, in particular, brings crucial changes to the Areas of Interest (AOIs) that are designed to align BARDA’s efforts with the evolving landscape of global health threats.

BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D Read More »

Stephen Richardson, Managing Consultant

Webinar: R&D Funding in Life Sciences: What's Ahead in Trump 2.0?